Immunophenotypic Markers and Antiretroviral Therapy (IMART): T cell activation and maturation help predict treatment response

Journal of Infectious Diseases

Volumn 189, Issue 10, 2004, Pages 1811-1820

  Mildvan, Donna ^a   Bosch, Ronald J ^b   Kim, Ryung S ^b   Spritzler, John ^b   Haas, David W ^d   Kuritzkes, Daniel ^c   Kagan, Jonathan ^e   Nokta, Mostafa ^g   DeGruttola, Victor ^b   Moreno, Melanie ^f   Landay, Alan ^h  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^g UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^h RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; VIRUS RNA;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DISEASE MODEL; DRUG RESPONSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; T LYMPHOCYTE ACTIVATION; TREATMENT FAILURE;

ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; HEMOGLOBINS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL;

EID: 2442655107     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/383277     Document Type: Article

References (78)

1. HIV Surrogate Marker Collaborative Group. Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate endpoints: a meta-analysis. AIDS Res Hum Retroviruses 2000; 16:1123-33.
2. Demeter LM, Hughes MD, Coombs RW, et al. Predictors of virologic and clinical outcomes in HIV-1 infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. Ann Intern Med 2001; 135:954-64.
3. Mildvan D, Landay A, De Gruttola V, Machado SG, Kagan J. An approach to the validation of markers for use in AIDS clinical trials. Clin Infect Dis 1997; 24:764-74.
4. Sabin C, Monforte AD, May M, et al. The changing incidence of clinical AIDS events in 12,574 treatment-naïve patients starting HAART [abstract 569]. Tenth Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003:261.
5. + lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996; 334:426-31.
6. Coombs RW, Welles SL, Hooper C, et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. J Infect Dis 1996; 174:704-12.
7. De Gruttola V, Fleming T, Lin DY, Coombs RW. Perspective: validating surrogate markers - are we being naive? J Infect Dis 1997; 175:237-46.
8. Machado SG, Gail MH, Ellenberg SS. On the use of laboratory markers as surrogates for clinical endpoints in the evaluation of treatment for HIV infection. J Acquir Immune Defic Syndr 1990; 3:1065-73.
9. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8:431-40.
10. Giorgi JV, Lyles RH, Matud JL, et al. Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr 2002; 29:346-55.
11. FDA Antiviral Drugs Advisory Committee. Session on the utility of plasma human immunodeficiency virus RNA measurement as an endpoint in clinical trials for drugs to treat HIV infection. Available at: http://www.fda.gov/ohrms/ dockets/ac/97/transcpt/3303tl.pdf. Accessed March 2003.
12. Murray JS, Elashoff MR, Iacono-Connors LC, Cvetkovich TA, Struble KA. The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. AIDS 1999; 13:797-804.
13. Lederman MM, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group protocol 315. J Infect Dis 1998; 178:70-9.
14. Havlir DV, Marschner IC, Hirsch MS, et al. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group protocol 343. N Engl J Med 1998; 339:1261-8.
15. Seth A, Markee J, Hoering A, et al. Alterations in T cell phenotype and human immunodeficiency virus type 1-specific cytotoxicity after potent antiretroviral therapy. AIDS Clinical Trials Group protocol 879. J Infect Dis 2001; 183:722-9.
16. Landay AL, Bettendorf D, Chan E, et al. Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease. AIDS Clinical Trials Group protocol 890. AIDS Res Hum Retroviruses 2002; 18:95-102.
17. Robbins G-K, De Gruttola V, Shafer RW, et al. Comparison on sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2293-303.
18. Adult Clinical Trials Group (ACTG) immunology consensus methodologies, 1997. Available at: http://aactg.s-3.com/immmeth.htm. Accessed March 2003.
19. Hughes MD. Analysis and design issues for studies using censored biomarker measurements with an example of viral load measurements in HIV clinical trials. Stat Med 2000; 19:3171-91.
20. Kent JT. Information gain and a general measure of correlation. Biometrika 1983; 70:163-73.
21. Valdez H, Connick E, Smith KY, et al. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002; 16:1859-66.
22. Kelleher AD, Carr, Zaunders J, et al. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996; 173:321-9.
23. + T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-6.
24. Connick E, Lederman MM, Kotzin BL, et al. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis 2000; 181:358-63.
25. Pakker NG, Notermans DW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998; 4:208-14.
26. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001; 28:445-9.
27. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 2002; 34:1115-21.
28. Spire B, Duran S, Souville M, Leport C, Raffi F, Moatti JP. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Soc Sci Med 2002; 54: 1481-96.
29. Wu H, Kuritzkes D, McClernon DR, et al. Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points. J Infect Dis 1999; 179:799-807.
30. + T cell levels: results of 6 years of follow-up: the Los Angeles Center, Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1993; 6:904-12.
31. + lymphocyte percent: a useful immunological marker for monitoring HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:158-62.
32. + T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:332-40.
33. Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179:859-70.
34. + T cells in HIV-infected patients. AIDS 1996; 10:827-34.
35. Benito JM, Zabay JM, Gil J, et al. Quantitative alterations of the functionally distinct subsets of CD4 and CD8 lymphocytes in asymptomatic infection: changes in the expression of CD45RO, CD45RA, CD11b, CD38, HLA-DR, and CD25 antigens. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:128-35.
36. + lymphocytes per microliter. AIDS Res Hum Retroviruses 1999; 15:1419-25.
37. + lymphocyte activation status and plasma RNA levels during antiretroviral therapy. AIDS 1998; 12:1267-73.
38. ++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection. AIDS 2002; 16:589-96.
39. Vigano A, Saresella M, Rusconi S, Ferrante P, Clerici M. Expression of CD38 on CD8 T cells predicts maintenance of high viraemia in HAART-treated HIV-1 infected children. Lancet 1998; 352:1905-6.
40. Sivadas R, Morrison S, Steigbigel RT. Abnormal immune activation persists years after control of HIV infection with HAART [abstract 496]. In: program and abstracts of the 40th Annual Meeting of the Infectious Diseases Society of America (Chicago). Alexandria, VA: Infectious Diseases Society of America, 2002:131.
41. Lange CG, Lederman MM, Madero JS, et al. Impact of suppression of viral replication by highly active antiretroviral therapy on immune function and phenotype in chronic HIV-1 infection. J Acquir Immune Defic Syndr 2002; 30:33-40.
42. Dyer WB, Kuipers H, Coolen MW, et al. Correlates of antiviral immune restoration in acute and chronic HIV type 1 infection: sustained viral suppression and normalization of T cell subsets. AIDS Res Hum Retroviruses 2002; 18:999-1010.
43. Zaunders JJ, Cunningham PH, Kelleher AD, et al. Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia. J Infect Dis 1999; 180:320-9.
44. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999; 340:1605-13.
45. Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999; 340:1614-22.
46. Gunthard HF, Havlir D, Fiscus S, et al. Residual human immunodeficiency virus (HIV) type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. J Infect Dis 2001; 183:1318-27.
47. Demeter LM, Bosch RJ, Coombs RW, et al. Detection of replication- competent human immunodeficiency virus type 1 (HIV-1) in cultures from patients with levels of HIV-1 RNA in plasma suppressed to less than 500 or 50 copies per milliliter. J Clin Microbiol 2002; 40:2089-94.
48. Layne SP, Merges MJ, Dembo M, et al. Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. Virology 1992; 189:695-714.
49. Piatak M, Saag MS, Yang LC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993; 259:1749-54.
50. Teixeira L, Valdez H, McCune JM, et al. Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS 2001; 15:1749-56.
51. Roederer M, Dubs JG, Anderson MT, Raju PA, Herzenberg LA, Herzenberg LA. CD8 naïve T cell counts decrease progressively in HIV-infected adults. J Clin Invest 1995; 95:2061-6.
52. + T cell repopulation of lymphoid tissues after treatment of HIV-1 infection. Proc Natl Acad Sci USA 1998; 95:1154-9.
53. Notermans DW, Pakker NG, Hamann D, et al. Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults. J Infect Dis 1999; 180:1050-6.
54. + naïve T cells following triple-drug therapy for HIV type 1 infection. AIDS Res Hum Retroviruses 1999; 15:435-43.
55. Hazenberg MD, Stuart JW, Otto SA, et al. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 2000; 95:249-55.
56. + count in HIV-infected patients at time of initiation of highly active antiretroviral therapy is strongly associated with the level of immunological recovery. Scand J Infect Dis 2002; 34:45-9.
57. + T cells enables preservation of naïve repertoire. J Immunol 1998; 161:5909-17.
58. + T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection. Clin Immunol 2002; 102:154-61.
59. Ascher MS, Sheppard HW. AIDS as immune system activation: a model for pathogenesis. Clin Exp Immunol 1988; 73:165-7.
60. Grossman Z, Herberman RB. T cell homeostasis in HIV infection is neither failing nor blind: modified cell counts reflect an adaptive response of the host. Nat Med 1997; 3:486-90.
61. Anderson RW, Ascher MS, Sheppard HW. Direct HIV cytopathicity cannot account for CD4 decline in AIDS in the presence of homeostasis: a worst-case dynamic analysis. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17:245-52.
62. + T cells go out of stock. Nat Immunol 2000; 1:285-9.
63. + T-cell depletion in HIV infection: are we closer to understanding the cause? Nat Med 2002; 8:319-23.
64. Sousa AE, Carneiro J, Meier-Schellersheim M, Grossman Z, Victorino RMM. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly linked to the viral load. J Immunol 2002; 169:3400-6.
65. + T cells correlate with plasma human immunodeficiency virus (HIV-1) RNA level in HIV infection. J Infect Dis 1998; 178: 1279-87.
66. Carbone J, Gil J, Benito JM, et al. Increased levels of activated subsets of CD4 T cells add to the prognostic value of low CD4 T cell counts in a cohort of HIV-infected drug users. AIDS 2000; 14:2823-9.
67. + T cells is markedly enhanced in the setting of antigen-specific immune activation. J Exp Med 1996; 183:687-92.
68. + T cells. Science 1999; 286:1353-7.
69. Lawn SD, Butera ST, Folks TM. Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency type 1 infection. Clin Microbiol Rev 2001; 14:753-77.
70. + lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest 1999; 103:1391-8.
71. Leng Q, Borkow G, Weisman Z, Stein M, Kalinkovich A, Bentwich Z. Immune activation correlates better than HIV plasma viral load with CD4 T-cell decline during HIV infection. J Acquir Immune Defic Syndr 2001; 27:389-97.
72. + T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187:1534-43.
73. + patients receiving lopinavir/ritonavir (Kaletra) [poster 5602612]. In: Program and abstracts of the Sixth International Congress on Drug Therapy in HIV Infection (Glasgow, 2002).
74. Post FA, Wood R, Maartens G. CD4 and total lymphocyte counts as predictors of HIV disease progression. Q J Med 1996; 89:505-8.
75. Beck EJ, Kupek EJ, Gompels MM, Pinching AJ. Correlation between total and CD4 lymphocyte counts in HIV infection: not making the good an enemy of the not so perfect. Int J STD AIDS 1996; 7:422-8.
76. Hosp M, Lisse IM, Quigley M, et al. An evaluation of low-cost progression markers in HIV-1 seropositive Zambians. HIV Med 2000; 1:125-7.
77. Kumarasamy N, Mahajan AP, Flanigan TP, et al. Total lymphocyte count (TLC) is a useful tool for the timing of opportunistic infection prophylaxis in India and other resource-constrained countries. J Acquir Immune Defic Syndr 2002; 31:378-83.
78. Gange SJ, Lau B, Phair J, Riddler SA, Detels R, Margolick JB. Rapid declines in total lymphocyte count and hemoglobin in HIV infection begin at CD4 lymphocyte counts that justify antiretroviral therapy. AIDS 2003; 17:119-21.